The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis

Schizophrenia Bulletin
Britta Hahn

Abstract

A major factor associated with poor prognostic outcome after a first psychotic break is cannabis misuse, which is prevalent in schizophrenia and particularly common in individuals with recent-onset psychosis. Behavioral interventions aimed at reducing cannabis use have been unsuccessful in this population. Cannabidiol (CBD) is a phytocannabinoid found in cannabis, although at low concentrations in modern-day strains. CBD has a broad pharmacological profile, but contrary to ∆9-tetrahydrocannabinol (THC), CBD does not activate CB1 or CB2 receptors and has at most subtle subjective effects. Growing evidence indicates that CBD acts as an antipsychotic and anxiolytic, and several reports suggest neuroprotective effects. Moreover, CBD attenuates THC's detrimental effects, both acutely and chronically, including psychotogenic, anxiogenic, and deleterious cognitive effects. This suggests that CBD may improve the disease trajectory of individuals with early psychosis and comorbid cannabis misuse in particular-a population with currently poor prognostic outcome and no specialized effective intervention.

References

Mar 1, 1976·Clinical Pharmacology and Therapeutics·W S DaltonR B Forney
Nov 1, 1991·Pharmacology, Biochemistry, and Behavior·P ConsroeK Schram
Sep 1, 1974·European Journal of Pharmacology·I G KarniolE A Carlini
May 1, 1981·Journal of Clinical Psychopharmacology·S S Matsuyama, T K Fu
Apr 1, 1994·Archives of General Psychiatry·D H LinszenM E Lenior
Sep 29, 1999·Neuroreport·F M LewekeD Piomelli
Jun 6, 2000·Pharmacology, Biochemistry, and Behavior·F M LewekeH M Emrich
Aug 2, 2000·Proceedings of the National Academy of Sciences of the United States of America·A M MalfaitM Feldmann
Nov 5, 2002·Journal of Clinical Pharmacology·Raphael MechoulamRuth Gallily
Sep 13, 2003·Lipids in Health and Disease·Nicola De MarchiVincenzo Di Marzo
Oct 30, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·José Alexandre de Souza CrippaGeraldo Filho Busatto
Feb 3, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Louise ArseneaultRobin M Murray
Feb 6, 2004·Archives of General Psychiatry·Ingrid MelleThomas McGlashan
Mar 3, 2004·The American Journal of Psychiatry·Natalie D VeenRené S Kahn
Sep 9, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Andrea GiuffridaDaniele Piomelli
Mar 23, 2005·Biological Psychiatry·Deepak Cyril D'SouzaJohn Harrison Krystal
Apr 23, 2005·Stroke; a Journal of Cerebral Circulation·Kenichi MishimaMichihiro Fujiwara
Jul 16, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·Anton GrechRobin M Murray
Jul 30, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Leonora E LongDavid A Taylor
Oct 4, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Bob GreenDavid Kavanagh
Jan 13, 2006·Journal of Psychopharmacology·Antonio Waldo ZuardiJosé Alexandre S Crippa
Aug 29, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Cécile HenquetJim van Os
Aug 23, 2007·Chemistry & Biodiversity·Marilyn A Huestis
Sep 19, 2007·British Journal of Pharmacology·E RybergP J Greasley
Apr 2, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Celia J A Morgan, H Valerie Curran
Apr 9, 2008·The Journal of Biological Chemistry·Hamish Redmond RossMark Connor
Jul 1, 2008·Biological Psychiatry·Stefan J BorgwardtPhilip K McGuire
Sep 20, 2008·Journal of Psychopharmacology·Aw ZuardiJec Hallak
Jan 7, 2009·Archives of General Psychiatry·Paolo Fusar-PoliPhilip K McGuire
Apr 2, 2009·The British Journal of Psychiatry : the Journal of Mental Science·Dagmar KoetheF Markus Leweke
Jun 11, 2009·Schizophrenia Bulletin·Cathrine MihalopoulosPatrick McGorry
Sep 5, 2009·Trends in Pharmacological Sciences·Angelo A IzzoRaphael Mechoulam

❮ Previous
Next ❯

Citations

May 24, 2018·Epidemiology and Psychiatric Sciences·G M MandoliniP Brambilla
Mar 19, 2020·European Archives of Psychiatry and Clinical Neuroscience·A TollA Mané
Feb 26, 2020·European Psychiatry : the Journal of the Association of European Psychiatrists·Teresa Sánchez-GutiérrezAna Calvo
Oct 18, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ferenc ZádorLászló Vécsei
Aug 15, 2019·Neurotoxicology·Stefania BonaccorsoFabrizio Schifano
Nov 29, 2020·Epilepsy & Behavior : E&B·Birgitta MetternichKerstin A Klotz
Jun 3, 2021·International Journal of Molecular Sciences·Ferenc ZádorLászló Vécsei
Jan 16, 2022·Neuropharmacology·Saeideh Karimi-HaghighiAbbas Haghparast

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
C D SchubartM P M Boks
The British Journal of Psychiatry : the Journal of Mental Science
C Henquet, Rebecca Kuepper
© 2022 Meta ULC. All rights reserved